US$13.75M financing completed to accelerate clinical pathway and global commercialisation

完成1375万美元融资，以加速临床路径和全球商业化进程

Establishment of NinaMED Pty Ltd, a new Australian medtech company

成立澳大利亚新医疗技术公司NinaMED Pty Ltd

NinaMED Pty Ltd secures a license from EBT Medical for exclusive global rights to NiNA System®, a non

NinaMED Pty Ltd 从 EBT Medical 获得 NiNA System® 的全球独家权利许可，这是一款非

‑

‑

invasive, at

侵入性的，处于...的

‑

‑

home OAB therapy targeting a 550 million

家庭OAB治疗，目标是5.5亿

‑

‑

patient market with a drug

用药物治疗的患者市场

‑

‑

free alternative

免费替代品

NinaMED Board chaired by Ian Meredith, bringing world

尼娜医疗董事会由伊恩·梅雷迪思主持，带来世界

‑

‑

class medtech leadership

医疗技术领导力课程

MELBOURNE, Australia

墨尔本，澳大利亚

,

，

May 13, 2026

2026年5月13日

/PRNewswire/ -- NinaMED Pty Ltd (NinaMED), a newly formed Australian medical device company, today announced its establishment and US $13.75 million (AUD $19 million) in financing led by SPRIM Global Investments (SGI). NinaMED holds an exclusive license from Toronto-based EBT Medical to develop and commercialise the NiNA System®— non-invasive, at-home, drug-free, therapy for overactive bladder (OAB)..

/PRNewswire/ -- 澳大利亚新成立的医疗设备公司NinaMED Pty Ltd（NinaMED）今日宣布成立，并获得由SPRIM环球投资（SGI）领投的1375万美元（约合1900万澳元）融资。NinaMED拥有来自多伦多EBT Medical的独家许可，用于开发和商业化NiNA系统®——一种针对膀胱过度活动症（OAB）的无创、家用、无药物疗法。

The NiNA System® is a non-invasive, wearable neuromodulation system that uses proprietary technology to activate NinaMED's patented saphenous nerve target. The novel patient-centric design enables convenient, in-home treatment sessions while significantly and persistently delivering reduced symptoms of OAB..

NiNA系统®是一种非侵入性、可穿戴的神经调节系统，利用专有技术激活NinaMED获得专利的隐神经靶点。这种新颖的以患者为中心的设计能够方便地进行居家治疗，同时显著且持续地减轻OAB（膀胱过度活动症）的症状。

Established and headquartered in Melbourne, NinaMED Pty Ltd is an Australian medical device company conducting clinical development in Australia for this worldwide commercialisation opportunity. The new financing will be used to accelerate development of the NiNA System®, support the path to an Investigational Device Exemption (IDE) Application, and build out the company's operations in Australia..

总部位于墨尔本的 NinaMED Pty Ltd 是一家澳大利亚医疗设备公司，正在澳大利亚进行该全球商业化机会的临床开发。新的融资将用于加速 NiNA 系统® 的开发，支持申请研究用器械豁免 (IDE) 的路径，并在澳大利亚拓展公司的运营。

NinaMED also announced its newly appointed Board of Directors, led by Chair Ian Meredith and Non-Executive Directors, Kelly Constable and Steffen Hovard, bringing deep medical device, healthcare, and global commercialisation experience to support the company's next phase of growth.

NinaMED 还宣布了其新任命的董事会，由主席伊恩·梅雷迪思 (Ian Meredith) 以及非执行董事凯利·康斯特布尔 (Kelly Constable) 和斯特芬·霍瓦德 (Steffen Hovard) 领导，他们带来了深厚的医疗器械、医疗保健和全球商业化经验，以支持公司下一阶段的增长。

'SPRIM is excited to announce the establishment of NinaMED as a new Australian medical device company and to have led this financing. The NiNA System® represents a compelling and differentiated solution in the large and growing OAB market. We look forward to supporting NinaMED as it advances NiNA towards worldwide commercialisation,' said Michael Shleifer, SPRIM Global Investments..

“SPRIM 很高兴宣布成立新的澳大利亚医疗设备公司 NinaMED，并主导了此次融资。NiNA System® 在庞大且不断增长的 OAB 市场中代表了一个引人注目且与众不同的解决方案。我们期待支持 NinaMED 推动 NiNA 在全球范围内的商业化，”SPRIM 全球投资公司的 Michael Shleifer 表示。

'SV Health Investors welcomes this important step forward for EBT Medical, the advancement of the NiNA System® technology and the establishment of NinaMED. NiNA addresses a significant unmet patient need with a compelling, novel approach. SV Health Investors looks forward to supporting the team as they advance this technology toward commercialisation.' said Gregory Madden, Managing Director of SV Health Investors and EBT Board Member..

“SV Health Investors欢迎EBT Medical迈出这一重要步伐，推动NiNA System®技术的发展，并成立了NinaMED。NiNA以一种引人注目的新颖方法满足了患者的重大未满足需求。SV Health Investors期待支持团队将这项技术推向商业化。”SV Health Investors董事总经理兼EBT董事会成员Gregory Madden表示。

'This financing marks an important milestone in the journey of a technology we have invested deeply in, and we are pleased to see NinaMED advancing toward commercialisation with the support of SPRIM and long-standing backer SV Health Investors. EBT will continue to develop Ina, its fully implantable saphenous nerve technology, as NinaMED advances NiNA System® toward commercialisation' said Keith Carlton, Co-Founder, Chief Executive Officer, and Board Member of EBT Medical Inc..

“这笔融资标志着我们深入投资的这项技术发展历程中的一个重要里程碑，我们很高兴看到NinaMED在SPRIM和长期支持者SV Health Investors的支持下朝着商业化迈进。EBT将继续开发其完全可植入的隐神经技术Ina，同时NinaMED将推动NiNA System®走向商业化。” EBT Medical Inc.联合创始人、首席执行官兼董事会成员Keith Carlton表示。

Newly appointed Chair of NinaMED, Professor Ian Meredith said 'I am excited by the strength and simplicity of the NiNA System® technology, the significant unmet need in pelvic health disorders, and the opportunity to be appointed Chair of NinaMED at such an important stage in its development. I look forward to working with the NinaMED team as it builds and maintains an Australian presence in support of a global commercialisation opportunity.'.

新任命的NinaMED主席伊恩·梅雷迪斯教授表示：“我对NiNA系统®技术的强大与简洁、盆腔健康疾病领域显著的未满足需求，以及在这一重要发展阶段被任命为NinaMED主席的机会感到兴奋。我期待与NinaMED团队合作，在支持全球商业化机遇的同时，建立并保持其在澳大利亚的影响力。”

OAB affects an estimated 550 million people worldwide and represents one of the most significant underserved conditions in urology. For patients who do not want to take another pill and are not ready for surgery, NiNA System® may be an ideal alternative. Current treatments — anticholinergic medications, beta-3 agonists, botulinum toxin injections, and sacral / tibial nerve stimulation — are associated with systemic side-effects, invasiveness, or the burden of frequent in-clinic procedures..

膀胱过度活动症（OAB）影响全球约5.5亿人，是泌尿科领域中最显著的未被充分满足的病症之一。对于不想再服用药丸且尚未准备好接受手术的患者，NiNA系统®可能是一个理想的替代方案。目前的治疗方法——抗胆碱能药物、β-3激动剂、肉毒杆菌毒素注射以及骶神经/胫神经刺激——均伴随着全身性副作用、侵入性操作或频繁到诊所进行治疗的负担。

The NiNA System® technology was discovered and patented at the University of Toronto by EBT Medical's co-founder, Professor Paul Yoo. The NiNA System® has been studied in multiple feasibility studies in the United States and Canada. The device targets the saphenous nerve — a shallow, sensory only nerve accessed in the upper calf — which operates via a centralised mechanism designed to deliver a safer, more efficacious, and more comfortable treatment experience compared with existing neuromodulation approaches..

NiNA系统®技术由EBT Medical的联合创始人、多伦多大学的保罗·余教授发现并获得专利。NiNA系统®已在美国和加拿大的多项可行性研究中进行了研究。该设备针对隐神经——一条位于小腿上部的浅层感觉神经，其通过集中机制运作，旨在提供比现有神经调节方法更安全、更有效且更舒适的治疗体验。

Board of Directors

董事会

NinaMED is pleased to announce the newly appointed Board members of NinaMED:

尼娜医药很高兴地宣布新任命的尼娜医药董事会成员：

Ian Meredith, MD — Chair, NinaMED

伊恩·梅雷迪思，医学博士 — 主席，NinaMED

Leading Australian interventional cardiologist and medtech executive who served as EVP and Global Chief Medical Officer at Boston Scientific, with extensive experience in medtech innovation and global healthcare leadership.

领先的澳大利亚介入心脏病学家和医疗科技主管，曾担任波士顿科学公司的执行副总裁兼全球首席医疗官，拥有丰富的医疗科技创新和全球医疗保健领导经验。

Kelly Constable — Non-Executive Director, NinaMED

凯莉·康斯特布尔 — 非执行董事，妮娜医疗

Experienced healthcare and medtech executive with a background in commercialisation, investment, and growth strategy across life sciences companies.

具有在生命科学公司商业化、投资和增长战略方面背景的资深医疗保健和医疗技术主管。

Steffen Hovard - Non-Executive Director, NinaMED

斯特芬·霍瓦德 - 非执行董事，尼娜医药

Healthcare executive with experience in medtech company leadership, commercial strategy, and innovation within the life sciences sector including direct prior relevant experience as President of Coloplast's Interventional Urology business and CEO of a start-up Sacral Neuromodulation company.

具有医疗技术公司领导、商业战略和生命科学领域创新经验的医疗保健高管，包括曾直接担任Coloplast介入泌尿业务总裁和一家骶神经调节初创公司首席执行官的相关经验。

In conjunction with the financing, EBT Medical is pleased to announce the appointment of

与融资同时进行，EBT Medical 很高兴地宣布任命

Ivan Jarry as Non-Executive Director

伊万·贾里任非执行董事

to its Board of Directors. Ivan is a global health and medtech investor with extensive experience building international businesses, venture platforms, and early-stage health technology companies.

加入其董事会。Ivan 是一位全球健康和医疗技术投资者，在建立国际业务、风险投资平台和早期健康技术公司方面拥有丰富经验。

Contact

联系

Keith Carlton

基思·卡尔顿

Ian Meredith

伊恩·梅雷迪思

EBT Medical, Inc.

EBT医疗公司

NinaMED Pty Ltd

尼娜医药有限公司

[email protected]

电子邮件地址

[email protected]

电子邮件地址

The NiNA System® is not approved for sale or commercial use in the United States, Canada or Australia.

NiNA系统®未获准在美国、加拿大或澳大利亚销售或商业使用。

The Nina System® is a registered trademark of EBT Medical, Inc. in Canada.

Nina系统®是EBT医疗公司（加拿大）的注册商标。

About EBT Medical, Inc.

关于EBT医疗公司

EBT Medical is the originator and licensor of the NiNA System® for overactive bladder, discovered and patented at the University of Toronto by EBT Medical's co-founder Professor Paul Yoo. EBT Medical is focused on advancing invasive neuromodulation solutions for pelvic health disorders starting with overactive bladder.

EBT Medical 是 NiNA System® 的发明者和授权方，该系统用于治疗膀胱过度活动症，由 EBT Medical 的联合创始人保罗·柳教授在多伦多大学发现并获得专利。EBT Medical 致力于推进针对盆底健康障碍的侵入性神经调节解决方案，首先从膀胱过度活动症开始。

For more information, visit: .

欲了解更多信息，请访问：。

www.ebtmedical.com

www.ebtmedical.com

.

。

About NinaMED Pty Ltd

关于NinaMED有限公司

NinaMED is an Australian proprietary limited, privately-held medical device company established to develop and commercialise the NiNA System® — a drug-free, noninvasive, at-home therapy for overactive bladder — under an exclusive license from EBT Medical, Inc.. Headquartered in Melbourne, Australia, NinaMED is building a world-class medical device program to bring meaningful relief to OAB patients globally.

NinaMED是一家澳大利亚私人控股的医疗设备公司，致力于开发和商业化NiNA系统®——一种无药物、非侵入式的家庭疗法，用于治疗膀胱过度活动症（OAB），并获得EBT Medical, Inc.的独家授权。总部位于澳大利亚墨尔本的NinaMED正在打造世界一流的医疗器械项目，旨在为全球OAB患者带来有效的缓解方案。

For more information, please visit: .

有关更多信息，请访问：。

www.meetninamed.com

www.meetninamed.com

.

。

About SPRIM Global Investments (SGI)

关于SPRIM环球投资（SGI）

Founded in 2008, SPRIM Global Investments (SGI) is a privately held investment firm specializing in clinical-stage life sciences and pharma services. SGI's innovative investment model provides agile and high-impact funding to high-potential biotech and medtech companies worldwide, supporting the advancement of clinical trials and accelerating the development of life-changing treatments.

成立于2008年的SPRIM环球投资（SGI）是一家私营投资公司，专注于临床阶段的生命科学和医药服务领域。SGI的创新投资模式为全球高潜力的生物技术和医疗技术公司提供灵活且高影响力的融资，支持临床试验的推进，并加速改变生命的治疗方法的开发。

For more information, visit: .

有关更多信息，请访问：。

www.sprim.net

www.sprim.net

.

。

About SV Health Investors

关于SV Health Investors

SV Health Investors is a specialist healthcare fund manager, investing across multiple stages and sectors through strategy-specific funds. SV invests across stages, geographic regions and sectors, with expertise spanning biotechnology, dementia, medical devices and services, and a proven track record of building world-class healthcare companies.

SV Health Investors 是一家专业的医疗保健基金管理公司，通过特定策略的基金在多个阶段和领域进行投资。SV 在不同阶段、地理区域和领域进行投资，其专业知识涵盖生物技术、痴呆症、医疗器械和服务，并拥有打造世界级医疗保健公司的成功记录。

For more information, visit: .

欲了解更多信息，请访问：。

www.svhealthinvestors.com

www.svhealthinvestors.com

.

。

SOURCE NinaMED Pty Ltd

来源：NinaMED Pty Ltd

21

21

%

%

more press release views with

更多新闻发布视图与

Request a Demo

请求演示